PBAC's latest decision on Follitropin alfa with lutropin alfa: Recommended with restriction (2024). Considered for Stimulation of follicular development in patients with severe LH deficiency undergoing assisted reproductive technology (IVF/GIFT) treatment.
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
Not modelled
no economic evaluation
Submissions
2
first 2018
Submissions
2
2018 → 2024
Eligible population
Women with severe LH deficiency undergoing assisted reproductive technology (IVF/GIFT treatment) who are considered appropriate for combination treatment with follitropin alfa 900 IU and lutropin alfa 450 IU.
Therapy area
Women's health
Line of therapy
Not applicable
Evidence base
Cost-minimisation
Primary endpoint
Cost-minimisation
Comparator
separate follitropin alfa (r-hFSH) and lutropin alfa (r-hLH) therapies
Economic model
BIA only
ICER note
No economic evaluation was performed; this is a minor submission requesting changes to quantity and clinical criteria for an already-listed medicine. Cost-minimisation only (administrative and financial burden reduction).
Submission history
Nov 2018: Recommended · Authority Required
Nov 2024: Recommended with restriction · Authority Required